March 2013 | Oncology & Biotech News

The Effect of Ipilimumab on Health-Related Quality of Life in Patients With Unresectable Advanced Melanoma

April 11, 2013

Patients diagnosed with melanoma are typically affected psychologically. Researchers summarized health-related quality of life (HRQOL) during the 12-week ipilimumab induction period in previously treated patients diagnosed with advanced stage III or IV melanoma.

(Molecular) Pathways, Pathways, and More Pathways

April 02, 2013

The oncology we all learned over the past three decades will soon be a thing of the past, making way for therapy decisions based on what molecular switches should be turned on and off, and of equal importance, in what sequence.

Trying to Calculate the Economic Value of Dasatinib or Nilotinib for Imatinib-Resistant CML

March 28, 2013

Although it is now standard practice to utilize the second-generation TKIs dasatinib or nilotinib in patients whose CML has recurred while taking imatinib treatment, published support for the economic value of this approach is lacking.